See what we’re reading this week at Global Biodefense on topics including a National Academies’ report on Dual Use Research of Concern, antibody therapeutics for ricinosis, and questions on inhaled flu vaccine [Read more]
Soligenix, Inc. announced today that it has been granted a Japanese patent (number 6110845) further extending protection around ThermoVax including coverage of the company’s ricin toxin vaccine candidate, RiVax. The technology is [Read more]
Soligenix, Inc. announced today that it has extended its collaboration with IDT Biologika for the manufacture of RiVax, the company’s proprietary heat-stable ricin toxin vaccine. Under the terms of the collaboration, Soligenix [Read more]
Soligenix, Inc. will present preclinical efficacy findings from its RiVax™ ricin toxin vaccine program at the National Organization for Rare Disorders’ (NORD’s) Rare Diseases and Orphan Products Breakthrough Summit on October 17-18, [Read more]
See what we’re reading this week at Global Biodefense on topics including plague vectors, next-generation antibiotics, and mapping zoonotic diseases. POLICY & PRACTICES The disease detective who speaks the truth about epidemics (Foreign Policy) [Read more]
The Food and Drug Administration has announced intentions to issue a sole-source award to Base Pair Biotechnologies to continue development of sensitive assays that can detect deadly ricin toxin. The contract supports the [Read more]
The U.S. Army’s Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) has again chosen Battelle to perform critical medical countermeasures research to protect servicemembers against dangerous infectious disease and chemical threats. [Read more]
See what we’re reading this week at Global Biodefense on topics including influenza surveillance programs, inadequate health emergency preparedness funding, and high containment ambulances. BIODEFENSE POLICY & PRACTICES Resilient health systems can prevent and [Read more]
Soligenix, Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option for RiVax™ bulk drug substance and finished drug product process scale-up and technology transfer. [Read more]
A 22 year old Chinese national Cheng Le, living in New York City, was sentenced last month to 16 years in prison for attempting to acquire ricin, postal fraud, and identity theft in [Read more]
© 2017 Global Biodefense